FDA ends for now use of two monoclonal antibodies, spurring a halt in federal shipments of the covid-19 treatments

The Food and Drug Administration on Monday took two monoclonal antibody therapies off the list of covid-19 treatments for now, saying the medications should not be used anywhere in the United States because they are ineffective against the dominant omicron variant.

As a result, the Biden administration said it will pause distribution of the therapies, manufactured by Regeneron Pharmaceuticals and Eli Lilly, to the states.